ACOR Financial Facts
Net sales: 128.51MTotal net revenues: 135.61M
See Full Income Statement
Cash and cash equivalents: 127.94M
Intangible assets, net of accumulated amortization: 749.42M
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
---|---|---|---|
Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
8/8/23 | Q223 | -$7.55 | N/A | N/A | $29.68M | N/A | N/A | Details | |||
5/4/23 | Q123 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
5/11/23 | Q123 | -$0.69 | N/A | N/A | $22.25M | N/A | N/A | Details | |||
2/16/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
2/27/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
2/20/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
3/6/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A | ||
3/9/23 | Q422 | N/A | -$0.15 | N/A | N/A | $35M | N/A | N/A | N/A |